AIFA – Indicazione terapeutica di empagliflozin negli adulti per il trattamento dell’insufficienza cardiaca cronica sintomatica con frazione di eiezione ridotta
16/05/2022
Leggi
Breaking news
Important Updates to the Standards of Medical Care in Diabetes—2022 Incorporate New Evidence:
Diabetes Care. 2022;45(Suppl. 1):S144–S174.
Diabetes Care. 2022;45(Suppl. 1):S175–S184.
Leggi
Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association
Pop-Busui R, Januzzi JL, Bruemmer D, et al.
Diabetes Care. dci220014
Leggi
Diabetic retinopathy screening in the emerging era of artificial intelligence
Grauslund J
Diabetologia. Pub. online 31 May 2022.
Leggi
Tirzepatide once weekly for the treatment of obesity
Jastreboff AM, Aronne LJ, Nadia N Ahmad, et al.
N Engl J Med. Pub. online 4 Jun 2022.
Leggi
Once-weekly dulaglutide for the treatment of youths with type 2 diabetes
Arslanian SA, Hannon T, Zeitler P, et al.
N Engl J Med. Pub. online 4 Jun 2022.
Leggi
Real-time CGM can predict severe hypoglycemia in people with type 1 diabetes: combined analysis of the HypoDE and DIAMOND trials
Hermanns N, Ehrmann D, Heinemann L, et al.
Diabetes Technol Ther. Pub. online 23 May 2022.
Leggi
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
Heise T, Mari A, DeVries JH, et al.
Lancet Diabetes Endocrinol. 2022;10(6):418-429.
Leggi
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes
Segar MW, Kolkailah AA, Frederich R, et al.
Diabetes Obes Metab. Pub. online 23 May 2022.
Leggi
Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada
Marfil-Garza BA, Imes S, Verhoeff K, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00114-0.
Leggi